Our community narratives are driven by numbers and valuation.
The global 'space economy' is forecasted to be worth ~$1.8 trillion by 2035. Roughly $800 billion is estimated to be made up of "backbone" business, such as satellites and rockets, and the services or software required to enable them, such as internet and positioning technologies.Read more
The average 12-month price target from analysts is IDR1,900. And then, The Discounted Cash Flow (DCF) model indicates an intrinsic value of approximately IDR1,631.09Read more

Excellon Resources Inc. is a Toronto-based mineral exploration and development company focused on silver and gold projects in Peru, the United States, and Germany.Read more

Catalysts Federal rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act is an inevitability from a scientific and sociopolitical perspective within five years. Rescheduling will eliminate the application of the punitive s.Read more
I was studying the company Dollar General #DG, a company that operates regular convenience stores in the USA targeting low and low-middle class audiences (that's how they politically correctly refer to poor people). They're interesting because their products are cheap, but per gram or liter of product they sell much more expensively.Read more

The company is a Spin off from HWO High Arctic Energy Services. HoH has assets (rigs) to operate in LNG extraction in PNG.Read more
Once again, I boldly foretell a future possibility for the years ahead. Some reading this may scoff, or may laugh and move on.Read more

Over the last year, the share price of Procter & Gamble (PG:NYSE) has fallen from around $175 to roughly $140, with most of the decline occurring since March. This weakness may partly reflect layoffs announced earlier in the year amid tariff-related uncertainty, and the stock may now be drifting into oversold territory.Read more

Key Takeaways Unicycive has completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC is designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability for dialysis patients with hyperphosphatemia.Read more
